Effects of doxorubicin, cisplatin, and tamoxifen on the metabolic profile of human breast cancer MCF-7 cells as determined by 1H HR-MAS NMR.
 

Effects of doxorubicin, cisplatin, and tamoxifen on the metabolic profile of human breast cancer MCF-7 cells as determined by 1H HR-MAS NMR.

Effects of doxorubicin, cisplatin, and tamoxifen on the metabolic profile of human breast cancer MCF-7 cells as determined by 1H HR-MAS NMR.

Biochemistry. 2017 Apr 05;:

Authors: Maria RM, Altei WF, Selistre-de-Araújo HS, Colnago LA

Abstract
Doxorubicin, cisplatin, and tamoxifen are part of many chemotherapeutic regimens. However, there are limited studies investigating the way metabolism in breast cancer is affected by chemotherapy. We studied, through 1H high-resolution magic angle spinning (HR-MAS) NMR spectroscopy, the metabolic profile of human breast cancer MCF-7 control (Con) cells as well as MCF-7 cells treated with tamoxifen (Tamo), cisplatin (Cis), and doxorubicin (Doxo). 1H HR-MAS NMR single pulse spectra evidenced signals from all mobile cell compounds, including fatty acids (membranes), water-soluble proteins, and metabolites. The spectra showed that phosphocholine (i.e., biomarker of breast cancer malignant transformation) signals were stronger in Con than in treated cells. Betaine (i.e., the major osmolyte in cells) was observed at similar concentrations in MCF-7 control and treated cells, but was absent in non-tumor MCF-10A cells. The NMR spectra acquired with Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence were used only in qualitative analyses because the signal areas were attenuated according to their transverse relaxation time (T2). The CPMG method was used to identify soluble metabolites such as organic acids, amino acids, choline and derivatives, taurine, and guanidinoacetate. 1H HR-MAS NMR spectroscopy efficiently demonstrated the effects of tamoxifen, cisplatin, and doxorubicin on the metabolic profile of MCF-7 cells. The fatty acid, phosphocholine, and choline variations observed by single pulse HR-MAS NMR have potential to characterize both responder and non-responder tumors in a molecular level.


PMID: 28379688 [PubMed - as supplied by publisher]



More...